Abstract -To enhance glioblastoma (GB) marker discovery, we compared gene expression in GB with human normal brain (NB) by accessing the SAGE Genie web site and compared the results with published data. Nine GB and five NB SAGE libraries were analyzed using the Digital Gene Expression Displayer (DGED); the results of DGED were tested by Northern blot analysis and RT-PCR of arbitrarily selected genes. Review of available data from the articles on gene expression profiling by microarray-based hybridization showed as few as 35 overlapped genes with increased expression in GB. Some of them were identified in four articles, but most genes were identified in three or even in two investigations. Some differences were also found between SAGE results of GB analysis. The Digital Gene Expression Displayer approach revealed 676 genes differentially expressed in GB vs. NB with cutoff ratio: twofold change and P ≤ 05. Differential expression of selected genes obtained by DGED was confirmed by Northern analysis and RT-PCR. Altogether, only 105 of 955 genes presented in published investigations were among the genes obtained by DGED. Comparison of the results obtained by microarrays and SAGE is very complicated because the authors present only the most prominent differentially expressed genes. However, even available data give quite poor overlapping of genes revealed by microarrays. Some differences between results obtained by SAGE in different investigations can be explained by high dependence on the statistical methods used. As for now, the best solution to search for molecular tumor markers is to compare all available results and to select only those genes where significant expression in tumors combined with very low expression in normal tissues was reproduced in several articles. One hundred five differentially expressed genes, common to both methods, can be included in the list of candidates for the molecular typing of GBs. Some genes, encoded cell surface or extracellular proteins may be useful for targeting gliomas with antibody-based therapy.
INTRODUCTION
Two newly developed high-throughput gene expression profiling technologies, microarray-based hybridization [1] [2] [3] and Serial Analysis of Gene Expression (SAGE) [4] [5] [6] have dramatically reshaped the biomedical research on elucidating the role of genes in cancer. However, despite the power of microarray-based hybridization and SAGE in the search for new molecular markers of human tumors, longstanding doubts persist as to the worth of the torrent of data that microarrays produce. Experiments have proved difficult to reproduce, and the lists of genes found in similar studies often have only limited overlap. The SAGE method also has its own problems: certain genes have no reliable tags; some tags have 1 The text was submitted by the authors in English. multiple matches against the EST databases. Also, sequencing errors could inflate the number of different tags. Alternative splicing of transcripts and sequence polymorphisms make the evaluation of results even more complicated, because multiple gene tags would correspond to a single gene.
To investigate the correlation and reproducibility between these currently often used approaches, we compared the available data obtained by microarray analysis and SAGE on changes of gene expression in glioblastoma, the most aggressive brain tumor that was the topic of our recent publications [7] [8] [9] . The practical aim of this study was to identify the changes of gene expression by comparison of results obtained by different approaches and described in different articles that might be helpful as molecular markers of glial tumors.
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MATERIALS AND METHODS
PubMed search with different combinations of keywords was performed to find the publications citing oligonucleotide and cDNA microarrays analysis for gene expression profiles in glioblastomas.
Nine SAGE libraries of glioblastoma (GB, WHO grade IV astrocytoma) and five normal adult human brain (NB) SAGE libraries were analyzed to compare gene expression by accessing the NCI CGAP web site (http://cgap.nci.nih.gov/SAGE) and using the search tool of Digital Gene Expression Displayer (DGED) provided by the SAGE Genie database. SAGE library GBM1062, also available in this database, prepared from tissue of a 4-month-old child, has a big difference in the gene expression profile as compared to adult tissue. For example, tag counts for C1QA, CD74, CHI3L1, COL1A1, GFAP, IGFBP7, and IGHG1 genes were very low in this library (8 tags for IGFBP7 gene, 18 tags for CD74 gene, and only 1 tag for the other five genes) in comparison with several hundred tags for each gene in adult GB tumors. Only SAGE libraries of a normal adult cortex, adult cerebellum, and adult thalamus have been chosen for the comparison. The available SAGE_Brain_fetal_normal_B_Sl and AGE_Brain_normal_peds_cortex_B_H1571 libraries, prepared from a fetal brain and the brain of a 15-month-old child, respectively, also differed very much in the gene expression profile as compared to adult NB libraries (data not shown). The SAGE_ Brain_normal_leptomeninges_B_AL2 library was originated from the tissue of nonglial origin, and the SAGE_Brain_normal_substantia_nigra_B_l library was from substantia nigra, which is not the place of glioma arising. The analysis was carried out under two different cutoff ratios (fivefold change and twofold change of gene expression) and significance filter P ≤ 0.05. The UniGene database of NCBI was searched to obtain the expressed sequence tags (ESTs) containing coding regions of corresponding mRNA. The selected cDNA clones were obtained from the German Resource Center for Genome Research (RZPD).
Brain tumor tissue samples were collected from the Romodanov Institute of Neurosurgery (Kyiv) under the approval of the Institute Review Board. Surgical specimens of histologically normal brain tissue adjacent to tumors were used as a source of normal adult human brain RNA. Northern analysis was performed as described in our previous works [8, 9] with the following probes for hybridization: annexin A1 (ANXA1) cDNA, clone IMAGp998L168452; beta-2-microglobulin (B2M) cDNA, clone IMAGp998I211214; CD74 antigen, invariant polypeptide of major histocompatibility complex, class II antigen-associated (CD74) cDNA, clone IMAGp998P 143584; complement component 1, q subcomponent, alpha polypeptide (C1QA) cDNA, clone IMAGp958J19l69; HC gp-39, human cartilage glycoprotein-39 (CHI3L1) cDNA, clone IMAGp998P09248; galectin 3 (LGALS3) cDNA, clone IMAGp998A089671; Sec61 gamma subunit (SEC61G) cDNA, clone IMAGp998G024700; secreted protein, acidic, cysteine-rich (osteonectin) (SPARC) cDNA, clone IMAGp998E214660; serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 (SERPINA3) cDNA, clone IMAGp958K06246; and 500 bp long RT-PCR product of β -actin mRNA. Hybridization bands were normalized to β -actin and compared by densitometric analysis of hybridization signals using the Scion Image 1.62c program.
Semi-quantitative RT-PCR with gene-specific primers was performed on normal brain and brain tumor RNA samples as described by Rae et al. [10] . Equal amounts of total cellular RNA (10 µ g each) were transcribed into cDNA with an oligo(dT) primer. PCR was performed in 20 µ l reaction mixture with cDNA synthesized from 0.5 µ g of total RNA, 2 U Taqpolymerase, 1 × PCR buffer, 0.2 mM dNTPs, and 1 µ M gene-specific primers: ABCC3 (for TGTCCCAC-CTGCACACGTTTG, rev CGTGTCATTCACCACT-TGGGG), COL1A1 (for GTGAACAAGGTCCCTCT-GGA, rev CGCCATACTCGAACTGGAAT), COL3A1 (for TTGACCCTAACCAAGGATGC, rev GTGTGT-TTCGTGCAACCATC), EGFR (for TGAAAACA-GCVTGCAAGGCCACA, rev ATGGCACAGGTGGA-CACATGG), FMOD (for CCTCCAAGGCAATAGGAT-CAAT, rev TGCCCATGCCACTGAAGTT), MFAP2 (for GTCCAACAGGAAGTCATCCCAG, rev GGGG-GACTGTCTGTCCTCVAAAA), and CHI3L2 (for GCA-GGAACCAGGAAAATTCAC, rev AGGCTTCTCT-TGACTGCTTGG). Thermal cycling parameters were as follows: denaturation at 94 ° C, 30 s; annealing at appropriate temperature for each primer pair, 1 min; synthesis at 72 ° C, 1 min for 30 cycles, followed by a further 7 min at 72 ° C. The number of cycles was then decreased until the PCR product amplification rate was in the linear phase (27 cycles). Amplified products were electrophoresed in a 2% agarose gel.
RESULTS AND DISCUSSION
Comparison of the published results of glioblastoma analysis by cDNA and oligonucleotide microchips. On May 1, 2006, we carried out a PubMed search and found 73 publications using the combination of words "microarray glioblastoma," 87 on "glioblastoma cDNA microarray," 54 on "glioblastoma gene expression microarray," and 82 on "glioblastoma oligonucleotide microarray." After removing redundancies and irrelevant publications, only 17 of 117 KAVSAN et al. Note: > means increase in expression, < means decrease in expression, ӷ 10 means increase in expression more than tenfold, Ӷ 10 means decrease in expression more than tenfold, Inc means increased expression in GB compared to NB, and Dec means decreased expression in GB compared to NB.
articles on gene expression profiling in glioblastoma by microarray technique where the authors compared gene expression profiles of native GBs and normal brain or lower grade gliomas and gave the names of differentially expressed genes remained for further analysis (Table 1) . In spite of different protocols and platforms used in microarray studies, we made an attempt to compare the described data and to reveal common genes with significantly changed expression in glioblastoma. Table 1 summarizes the characteristics of microchips, total quantity of overexpressed genes, quantity of described genes, and tissues that were compared in these studies.
Unfortunately, the authors present in their articles only the most prominent differentially expressed genes; however, even comparison of available data shows quite poor overlapping of genes revealed by microarrays, as one can see in Table 2 . Only a limited number of 849 described differentially expressed in GB genes were identified in at least 4 of 17 investigations with the microarray approach; other overlapped genes were described only in three or even in two different articles. The poor overlapping of the results obtained by the microarray approach can be partially explained by different numbers of genes analyzed in different works. In particular, the first Clontech cDNA arrays contained overly small sets of genes. However, even the studies with the same type of microchips did not show significant reproducibility. For example, the Hu6800 GeneChip was used in three works [17] [18] [19] , but only one of the described genes, TOP2A, was found to be common between [17] and [19] and another gene, IGFBP4, was common for [18] and [19] . The explanation of such significant differences in obtained results was given in four recently appearing independent studies [28] [29] [30] [31] , which confirmed three persistent criticisms of the method: that the bewildering array of platforms and research protocols available can make results from different studies hard to compare; that, in the hands of less experienced labs, homemade arrays are less dependable than commercial chips; and that different labs doing the same study can often get very different results [32] .
Determination of glioblastoma-associated genes by DGED analysis and comparison with published data obtained by microarray techniques. SAGE tag frequencies depend largely on the total number of tags counted [33, 34] . If more tags were counted, then the tag frequency for each gene would be higher. In our previous work [8] , the comparison of five GB SAGE libraries with two NB SAGE libraries that were available that time has revealed 117 genes with more than a fivefold difference at the P ≤ 0.05 level. Of these 117 genes, 24 increased their expression in GBs. Four new GB SAGE libraries have appeared recently in the SAGE Genie database. Comparing all nine GB tumor SAGE libraries with five NB SAGE libraries (cutoff ratio: fivefold change, P ≤ 0.05), the number of tags was 129 when gene tags that had no reliable matches in UniGene clusters, mitochondrial genes, ESTs, and the lower ranked tag (if more than one gene tag corresponded to the same UniGene cluster) were excluded from the list. Forty-four genes met the criteria for genes overexpressed and 85 genes met the criteria for genes down-regulated in tumors (Supplementary Table 1 ). In this table, the final column gives, for each gene (i.e., tag), the overall ratio for all of the GB samples, taken together as a group, to all of the NB samples, at a significance of P ≤ 0.05. In most cases, genes were overexpressed by more than tenfold.
Two main questions are critical in such investigations: above what threshold does the overexpression of a particular gene have to be considered as significant and relevant and what are the diagnostic, pathophysiological, and therapeutic consequences of such overexpression? While there is no answer to the second question for any particular gene, every group of authors make their own decision. For example, Lal et al. [34] investigated genes that were differentially expressed by more than fivefold with P ≤ 0.001; Loging et al. [35] used the same approach and investigated genes that changed their expression tenfold with P ≤ 0.001. Markert et al. [18] discussed the possible participation in tumor initiation and progression even for those genes that were differentially expressed less than twofold with P ≤ 0.05, although they focused on genes with fivefold change in expression. Ljubimova et al. [20] detected by GEM array a total of about 3000 genes with changed expression in GBs. Of these genes, 14 were significantly (with ratios of ≥ 2) up-regulated and 12 genes were down-regulated. Selecting a cutoff ratio of less than fivefold change would lead to obtaining more overexpressed genes; however, genes exhibiting high differences in expression are likely to be more biologically relevant.
To compare SAGE results on genes that changed their expression in GB with those obtained by the microarray technique, the expression factor 2 and significance filter P ≤ 0.05 were chosen because these parameters were used mostly in the microarray analyses. The comparison of the pools of nine GB SAGE libraries and five NB SAGE libraries has revealed 1303 tags. Most of the matching transcripts corresponded to characterized mRNA sequence entries, whereas 253 tags matched uncharacterized ESTs. When genes with no tags and tags that matched multiple genes were excluded, more than twofold differences of the expression were shown for 676 genes, of which 316 genes were determined as overexpressed. The most detailed description of data obtained by microarray analysis was given by Markert et al. [18] . We compared their data with our SAGE results and revealed 51 common genes (Table 3) . Conversion from gene names to tags or from tags to genes was performed at the SAGEmap site (http://www.ncbi.nlm.nih.gov/SAGE/). To collate SAGE tags with GeneChip probe sets representing GenBank accession numbers, GenBank accession numbers were converted into UniGene clusters. Several genes had a good reproducibility by both methods. For example, expression of human cartilage glicoprotein (HC gp-39) gene was increased more than tenfold (P = 0.038) according microarray analysis and tag odds was 70.92 according SAGE. However, probability level P ≤ 0.05 was obtained by Markert et al. [18] only for 10 of these 51 genes and there was no good correlation for several other genes with P > 0.05 between the two methods. For example, tag odds for FN1 gene was 21.96, but in microarray analysis, its expression level was increased only 1.2-fold (P = 0.862). Moreover, for several genes (PKC beta-1, SPARC, and UBB), the results of microarray analysis are in contrast to SAGE: decrease in the expression instead of increase and vice versa.
Comparison of our SAGE results on genes overexpressed in GB shows only 3 common genes of 6 genes described by Fuller et al. [11] [25] , 11 of 99 genes described by Yokota et al. [26] , and 2 of 8 by Liau et al. [27] . Altogether, 105 of 849 described genes were overlapping in comparison with our results obtained by SAGE ( Table 4) . As one can see, the main problem in evaluation of results obtained by comparison of gene expression in glioblastomas and normal brain samples is the lack of available data from each paper. The reason of poor overlapping of genes revealed by microarrays apparently is due to methodological artifacts (e.g., different gene numbers placed onto chips, poor quality of synthesized total cDNA probes or high background of hybridization patterns, and problems with housekeeping gene controls) as well as to biological reasons (e.g., heterogeneity of molecular mechanisms of glioblastoma formation). A very big problem is obtaining normal brain samples. Most often, surgical specimens of histologically normal brain, adjacent to the tumor, are used as the source of NB RNA; however, they can be considered as a normal control only with some precautions: gliomas are infiltrating tumors and scattered tumor cells are present far away from the dense tumor area removed during surgery.
Comparison with published results obtained by SAGE. As of May 2006, using the combination of words "SAGE and glioblastoma," we found only ten publications. Evidently, the application of SAGE to the field of gene expression profiles for glioblastoma tumor and glioblastoma cell culture is just a beginning. The first SAGE analysis of GB compared two GB SAGE libraries vs. two NB SAGE libraries and showed that 1.0% (471) of the transcripts had more than a fivefold (P ≤ 0.001) of the 47 174 unique transcripts expressed in these two tissues [34] . Soon after this work, the SAGEmap database was chosen by Loging et al. [35] , who revealed 76 genes (0.16%) as overexpressed in glioblastomas to the order of tenfold or more and with P values <0.001. Again, the authors mention only selected genes with a distinct difference in transcript levels between NB and GB samples. Three of the discussed genes were described previously by Lal et al. [34] . Using the search tool DGED provided by the SAGE Genie database and the same fivefold cutoff ratio for the comparisons of each gene, with a concomitant statistical likelihood of P ≤ 0.05, we found only 33 differentially expressed transcripts when comparing pools of the same GB and NB SAGE libraries used by Lal et al. [34] and Lodging et al. [35] . Such a large discrepancy in the number of genes that are over-or underexpressed in one sample relative to another at a given significance level can be explained by a very high dependence on the statistical methods used.
Boon et al. [36] selected tags with at least a tenfold overexpression in gliomas. Despite the high heterogeneity among tumors, a small set of genes was consistently observed at high levels in more than a third of each grade of astrocytoma. The authors presented a list of 18 selected highly expressed genes in GB; only six of them were described previously by Lal et al. [34] , and one gene (SEC61G) was described by Loging et al. [35] . Using Long SAGE libraries that contain 17 bp tags, Madden et al. [37] revealed 122 genes that were induced (fourfold induction ratio) in the glioma endothelial cells. These 122 genes were narrowed to 14 by applying additional statistical filters. The authors analyzed gene expression in endothelial cells, which may be an explanation of why only one gene (COL6A2) was common with SAGE data of other authors.
Comparison of 74 genes obtained by SAGE and described in four cited articles [34] [35] [36] [37] with results of DGED analysis that we performed on 9 GB and 5 NB SAGE libraries from SAGE Genie showed 32 common genes for F (expression factor): 5X and P (significance filter): 0.05, and 54 common genes for F: 2X and P: 0.05. The fact that not all 74 mentioned genes were revealed by DGED can be explained by different sets of libraries analyzed in different works: Lal et al. [34] and Loging et al. [35] analyzed two GB and two NB SAGE libraries; Boon et al. [36] compared the pool of the same GB SAGE libraries as we did, but to the pool of 5 NB SAGE libraries, they added libraries of substantia nigra, pediatric cortex, and normal leukocytes. Loging et al. [35] and Boon et al. [36] gave genes only with increased expression in GB but did not discuss genes with down-regulated expression. In addition, the obtained differences may be explained by a high dependence on the statistical methods used.
Apparently, the best solution of the problem is to compare all available data and to select only those genes where significant expression in tumors combined with no detectable expression in normal tissues was reproduced in several articles. Because of the potential problems with normalization and other pos-sible errors, it is best to base the decision to proceed with investigating a candidate tumor marker only on absolute differences in expression between tumor and normal tissues and not on small ratios of change [36] . After a gene expression profile has been obtained on a set of RNA samples, the expression differences need to be confirmed and it is often useful to determine if the observation is repeatable in independent samples [38] . Northern blotting has been the gold standard for gene expression analysis for many years. To assess the reliability of expression patterns, we arbitrarily selected ten differentially expressed transcripts and evaluated them by Northern blot analysis, also allowing detection of alternative transcripts when their expression level was sufficient. Expression patterns were usually reproducible between different samples of an independent set of tumors and normal tissue: genes with elevated expression in glioblastoma relative to normal brain as determined by SAGE were detected in most of the GB samples and were expressed at considerably lower levels in most samples of normal brain ( Fig. 1-6 ). Differences in expression between individual tumors, exhibiting either high or low amounts of individual transcripts, undoubtedly contribute to the observed heterogeneity in the biological properties of glioblastomas.
When gene expression levels were too low to detect by Northern analysis, we used semiquantitative RT-PCR and confirmed increased expression of ABCC3, COL1A1, COL3A1, EGFR, CHI3L2, FMOD, and MFAP2 genes in 30-80% of GBs (Fig. 7) . In other investigations, real-time PCR was used to confirm the results obtained by microarray analysis for BMP2, DLL3, HDAC4, EDNRB, IP3K, RGS4, SYT1, VSNL1, MET, TOP2A, IGF2, CDC2, COL6A3, IGFBP4, LOX, and THBS1 genes [25] and SAGE results for ABCC3, ANXA1, GPNMB, NMB, NNMT, SEC61G [35] , AQP1, TYMS, TOP2A, ABCC3, SAA1, CHI3L2, NMB, and MGP genes [36] .
The confirmation of microarray or SAGE results on the protein level is advantageous when the endpoint is knowledge of protein levels rather than mRNA levels. Unfortunately, expression changes on the protein level were analyzed in reviewed publications with SAGE only for three genes. TOP2A and AQP1 were revealed in more than half of GBs by immunohistochemistry [36] . Elevation of YKL-40 (CHI3L1) in 65 GBs was shown by Western blotting, and as detected by ELISA analysis, YKL-40 was at substantially higher levels in serum of many GB patients [21] . We compared the production of YKL-40 protein in GB and NB by Western blotting and found a much higher level of expression of YKL-40 in GB than in oligoastrocytoma, adult NB, fetal brain, and fetal liver (Fig. 8) . LGALS3 β-actin
mRNA expression level, arbitrary units In addition, we revealed larger sizes of YKL-40 bands in all three GBs analyzed in addition to 39 kDa protein described for the chondrocytes and synovial cells [39] .
CONCLUSIONS
In this work, we intended to find the overlapping genes with significantly enhanced expression in glioblastoma by comparing the results of different scientific groups obtained by two modern techniquesmicroarray-based hybridization and SAGE.
Unfortunately, the authors present only the most prominent differentially expressed genes as compared to normal brain, but even comparison of available data shows quite poor overlapping of genes revealed by microarrays. The comparison of microarray analysis with SAGE showed more overlapping genes changing their expression in GB than between results obtained by microarrays owing to the higher sensitivity of SAGE, which permits the differences to be revealed even for rare transcripts. However, even the results of SAGE described in different articles are not completely reproducible, which can be explained at least partially by a high dependence on the statistical methods used. Apparently, the best solution of the problem in searching GB markers is to compare all available results and to select only those genes where significant expression in tumors combined with no detectable or very low expression in normal tissues was reproduced in several articles. One hundred five differentially expressed genes, common to both methods, can be included in the list of candidates for the molecular typing of GB. Northern analysis and semiquanti- tative RT-PCR of arbitrarily selected differentially expressed transcripts confirmed this result. Some genes, encoded cell surface or extracellular proteins may be useful for targeting gliomas with antibodybased therapy.
